IP Library › Granted Patent US 12,209,260

Granted Patent B2

US 12,209,260 · App. 17/251,266 · Granted Jan 28, 2025

Protease specific for a novel sumo-derived protease cleavage site

Inventors: Arturo Vera Rodriguez (Göttingen, DE); Dirk Görlich (Göttingen, DE); Steffen Frey (Göttingen, DE)

Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.

C12N9/60 C07K1/22 C07K2319/50

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,209,260
App. No.: 17/251,266
Granted: Jan 28, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to a fusion protein, comprising the structure N-PCS Y -degSig N -M-PCS X -degSig C -C; wherein N represents the N-terminus; PCS Y and PCS X each represent a protease cleavage site (PCS), which differ from each other in at least one amino acid residue: degSig N represents a degradation signal which promotes degradation of the fusion protein in a host cell if PCS Y is cleaved by a protease such that the first amino acid of degSig N becomes the new N-terminus of the remaining fusion; M represents a cytoplasmic selection marker; and degSig C represents a second degradation signal which promotes degradation of the fusion protein in a host cell if PCS X is not cleaved by a protease; and C represents the C-terminus. Further provided is a nucleic acid construct, comprising a nucleic acid sequence coding for said fusion protein, a nucleic acid expression construct library, comprising a plurality of such nucleic acid expression constructs in diversified form, and methods using the fusion protein and nucleic acid constructs coding therefor. Finally, the present invention provides variants of bdSUMO and bdSENP1 which have been identified by the methods of the present disclosure, and which exhibit improved properties over existing orthogonal protease/protease cleavage site-pairs which are currently used with wild-type bdSUMO and wildtype bdSENP1.

Claims (54)

1. A variant protease,

wherein said variant protease has at least 96% sequence identity over the full-length of the polypeptide of SEQ ID NO:6,

wherein said variant protease comprises an amino acid substitution at the position corresponding to position 33 of the protein of SEQ ID NO: 6, wherein the amino acid at said position is substituted by an amino acid selected from the group consisting of S, H, Q, A, G, and C, and

wherein said variant protease cleaves a first protease cleavage site (PCS) in a first fusion protein that comprises a maltose-binding protein (MBP) and said first PCS, wherein said first PCS is fused to the N-terminus of the MBP (first PCS-MBP fusion protein), wherein said first PCS has the amino acid sequence of SEQ ID NO: 41 and the MBP has the amino acid sequence of SEQ ID NO: 71, more efficiently after the C-terminal Gly-Gly motif of the first PCS of SEQ ID NO: 41 than said variant protease cleaves

(i) a second PCS in a second fusion protein that comprises a MBP and said second PCS, wherein said second PCS is fused to the N-terminus of the MBP (second PCS-MBP fusion protein), wherein said second PCS has the amino acid sequence of SEQ ID NO: 4 and the MBP has the amino acid sequence of SEQ ID NO: 71, wherein the cleavage occurs after the C-terminal Gly-Gly motif of the second PCS of SEQ ID NO: 4, or

(ii) a third PCS in a third fusion protein that comprises a MBP and said third PCS, wherein said third PCS is fused to the N-terminus of the MBP (third PCS-MBP fusion protein), wherein said third PCS has the amino acid sequence of SEQ ID NO: 3 and the MBP has the amino acid sequence of SEQ ID NO: 71, wherein the cleavage occurs after the C-terminal Gly-Gly motif of the third PCS of SEQ ID NO: 3,

when tested in a buffer under standard conditions of 1 hour incubation at 21° C., wherein said buffer comprises an initial concentration of the first, second and third PCS-MBP fusion proteins of 100 μM, and wherein the buffer comprises a pH of 7.5, Tris/HCl at a concentration of 45 mM, NaCl at a concentration of 250 mM, MgCl 2 at a concentration of 2 mM, sucrose at a concentration of 250 mM, and DTT at a concentration of 10 mM.

2. The variant protease of claim 1 , wherein said variant protease cleaves the first PCS-MBP fusion protein at said standard conditions and at an at least 500-fold molar excess of said PCS-MBP fusion protein compared to the amount of said protease.

3. The variant protease of claim 1 , wherein the amino acid at the position corresponding to position 33 of the protein of SEQ ID NO: 6 is selected from the group consisting of S, H, Q, and A.

4. The variant protease of claim 1 , wherein said variant protease further comprises an amino acid substitution at the position corresponding to position 99 of the protein of SEQ ID NO: 6, wherein the amino acid at said position is substituted by another amino acid selected from the group consisting of E, S, V, Y, and L.

5. The variant protease of claim 4 , wherein the amino acid at the position corresponding to position 99 of the protein of SEQ ID NO: 6 is substituted by an amino acid selected from the group consisting of E, S, and V.

6. The variant protease of claim 4 , wherein said variant protease further comprises an amino acid substitution at the position corresponding to position 22 of the protein of SEQ ID NO: 6, wherein the amino acid at said position is substituted by another amino acid selected from the group consisting of E, S, P, K, and V.

7. The variant protease of claim 4 , wherein said variant protease further comprises an amino acid substitution at the position corresponding to position 103 of the protein of SEQ ID NO: 6, wherein the amino acid at said position is substituted by another amino acid selected from the group consisting of M, E, V, G, T, and R.

8. The variant protease of claim 7 wherein the amino acid at the position corresponding to position 103 of the protein of SEQ ID NO: 6 is substituted by an amino acid selected from the group consisting of M, E, V, G and T.

9. The variant protease of claim 1 , wherein said variant protease further comprises two or three amino acid substitutions at positions corresponding to positions of the protein of SEQ ID NO: 6 selected from the group consisting of positions 99, 22, and 103, wherein

the amino acid substitution at the position corresponding to position 99 of the protein of SEQ ID NO: 6 is a substitution by an amino acid selected from the group consisting of E, S, V, Y, and L,

the amino acid substitution at the position corresponding to position 22 of the protein of SEQ ID NO: 6 is a substitution by an amino acid selected from the group consisting of E, S, P, K, and V, and

the amino acid substitution at the position corresponding to position 103 of the protein of SEQ ID NO: 6 is a substitution by an amino acid selected from the group consisting of M, E, V, G, T, and R.

10. The variant protease of claim 1 , wherein said variant protease comprises a combination of amino acid substitutions selected from the group consisting of

(i) amino acid substitutions at the positions corresponding to positions 33 and 99 of the protein of SEQ ID NO: 6, wherein the amino acid at the position corresponding to position 33 of the protein of SEQ ID NO: 6 is S, and the amino acid at the position corresponding to position 99 of the protein of SEQ ID NO: 6 is E;

(ii) amino acid substitutions at the positions corresponding to positions 22, 33 and 103 of the protein of SEQ ID NO: 6, wherein the amino acid at the position corresponding to position 33 of the protein of SEQ ID NO: 6 is H, the amino acid at the position corresponding to position 22 of the protein of SEQ ID NO: 6 is S, and the amino acid at the position corresponding to position 103 of the protein of SEQ ID NO: 6 is V;

(iii) amino acid substitutions at the positions corresponding to positions 22, 33, 99 and 103 of the protein of SEQ ID NO: 6, wherein the amino acid at the position corresponding to position 22 of the protein of SEQ ID NO: 6 is P, the amino acid at the position corresponding to position 33 of the protein of SEQ ID NO: 6 is A, the amino acid at the position corresponding to position 99 of the protein of SEQ ID NO: 6 is E, and the amino acid at the position corresponding to position 103 of the protein of SEQ ID NO: 6 is M;

(iv) amino acid substitutions at the positions corresponding to positions 22, 33, 99 and 103 of the protein of SEQ ID NO: 6, wherein the amino acid at the position corresponding to position 22 of the protein of SEQ ID NO: 6 is K, the amino acid at the position corresponding to position 33 of the protein of SEQ ID NO: 6 is H, the amino acid at the position corresponding to position 99 of the protein of SEQ ID NO: 6 is E, and the amino acid at the position corresponding to position 103 of the protein of SEQ ID NO: 6 is E;

(v) amino acid substitutions at the positions corresponding to positions 22, 33, 99 and 103 of the protein of SEQ ID NO: 6, wherein the amino acid at the position corresponding to position 22 of the protein of SEQ ID NO: 6 is E, the amino acid at the position corresponding to position 33 of the protein of SEQ ID NO: 6 is S, the amino acid at the position corresponding to position 99 of the protein of SEQ ID NO: 6 is S, and the amino acid at the position corresponding to position 103 of the protein of SEQ ID NO: 6 is T; and

(vi) amino acid substitutions at the positions corresponding to positions 22, 33, 99 and 103 of the protein of SEQ ID NO: 6, wherein the amino acid at the position corresponding to position 22 of the protein of SEQ ID NO: 6 is V, the amino acid at the position corresponding to position 33 of the protein of SEQ ID NO: 6 is Q, the amino acid at the position corresponding to position 99 of the protein of SEQ ID NO: 6 is V, and the amino acid at the position corresponding to position 103 of the protein of SEQ ID NO: 6 is G.

11. The variant protease of claim 1 , wherein said variant protease comprises all of SEQ ID NO: 6, except for:

(a) the amino acid substitution at the position corresponding to position 33 of the protein of SEQ ID NO: 6, or

(b) the amino acid substitution at the position corresponding to position 33 of the protein of SEQ ID NO: 6 and one or more amino acid substitutions at positions corresponding to positions of the protein of SEQ ID NO: 6 selected from 22, 99, and 103.

12. The variant protease of claim 1 having the amino acid sequence of any one of SEQ ID NO: 56, 57, 58, 60, 61, 62, 63, 64, 65 or 66.

13. A process of purifying a protein of interest, comprising the steps of

(i) providing a protein of interest to be purified, wherein said protein comprises an affinity tag fused to said protein via a protease cleavage site (PCS);

(ii) binding the protein of step (i) to an affinity matrix via said affinity tag; and

(iii) eluting the protein from the affinity matrix using the variant protein of claim 1 , thereby purifying the protein.

14. The process of claim 13 , wherein said PCS has at least 96% sequence identity over the full-length of the polypeptide of SEQ ID NO: 3,

wherein said PCS comprises an amino acid substitution at the position corresponding to position 67 of the protein of SEQ ID NO: 3, wherein the amino acid at said position is substituted by another amino acid selected from the group consisting of K, R, N, A and H, and

wherein said PCS comprises a C-terminal Gly-Gly motif.

15. The process of claim 14 , wherein said PCS further comprises:

(a) an amino acid substitution at the position corresponding to position 75 of the protein of SEQ ID NO: 3, wherein the amino acid at said position is substituted by another amino acid selected from the group consisting of R, W, A, H, M, I, P, and F; and/or

(b) an amino acid substitution at the position corresponding to position 60 of the protein of SEQ ID NO: 3, wherein the amino acid at said position is substituted by another amino acid selected from the group consisting of S, N, K, P, HR, and Q.

16. The process of claim 14 , wherein said PCS comprises a combination of amino acid substitutions selected from the group consisting of

(i) amino acid substitutions at the positions corresponding to positions 67, 60 and 75 of the protein of SEQ ID NO: 3, wherein the amino acid at the position corresponding to position 67 of the protein of SEQ ID NO: 3 is K, the amino acid at the position corresponding to position 60 of the protein of SEQ ID NO: 3 is K, and the amino acid at the position corresponding to position 75 of the protein of SEQ ID NO: 3 is R;

(ii) amino acid substitutions at the positions corresponding to positions 67, 60 and 75 of the protein of SEQ ID NO: 3, wherein the amino acid at the position corresponding to position 67 of the protein of SEQ ID NO: 3 is K, the amino acid at the position corresponding to position 60 of the protein of SEQ ID NO: 3 is P, and the amino acid at the position corresponding to position 75 of the protein of SEQ ID NO: 3 is W;

(iii) amino acid substitutions at the positions corresponding to positions 67 and 75 of the protein of SEQ ID NO: 3, wherein the amino acid at the position corresponding to position 67 of the protein of SEQ ID NO: 3 is K, and the amino acid at the position corresponding to position 75 of the protein of SEQ ID NO: 3 is R;

(iv) amino acid substitutions at the positions corresponding to positions 67, 60 and 75 of the protein of SEQ ID NO: 3, wherein the amino acid at the position corresponding to position 67 of the protein of SEQ ID NO: 3 is K, the amino acid at the position corresponding to position 60 of the protein of SEQ ID NO: 3 is S, and the amino acid at the position corresponding to position 75 of the protein of SEQ ID NO: 3 is H;

(v) amino acid substitutions at the positions corresponding to positions 67, 60 and 75 of the protein of SEQ ID NO: 3, wherein the amino acid at the position corresponding to position 67 of the protein of SEQ ID NO: 3 is K, the amino acid at the position corresponding to position 60 of the protein of SEQ ID NO: 3 is S, and the amino acid at the position corresponding to position 75 of the protein of SEQ ID NO: 3 is W;

(vi) amino acid substitutions at the positions corresponding to positions 67, 60 and 75 of the protein of SEQ ID NO: 3, wherein the amino acid at the position corresponding to position 67 of the protein of SEQ ID NO: 3 is K, the amino acid at the position corresponding to position 60 of the protein of SEQ ID NO: 3 is S, and the amino acid at the position corresponding to position 75 of the protein of SEQ ID NO: 3 is A;

(vii) amino acid substitutions at the positions corresponding to positions 67, 60 and 75 of the protein of SEQ ID NO: 3, wherein the amino acid at the position corresponding to position 67 of the protein of SEQ ID NO: 3 is K, the amino acid at the position corresponding to position 60 of the protein of SEQ ID NO: 3 is N, and the amino acid at the position corresponding to position 75 of the protein of SEQ ID NO: 3 is W; and

(viii) amino acid substitutions at the positions corresponding to positions 67, 60 and 75 of the protein of SEQ ID NO: 3, wherein the amino acid at the position corresponding to position 67 of the protein of SEQ ID NO: 3 is K, the amino acid at the position corresponding to position 60 of the protein of SEQ ID NO: 3 is N, and the amino acid at the position corresponding to position 75 of the protein of SEQ ID NO: 3 is A.

17. The process of claim 13 , wherein said PCS has the amino acid sequence of SEQ ID NO: 3 except for an amino acid substitution at the position corresponding to position 67 of the protein of SEQ ID NO: 3, wherein the amino acid at said position is K.

18. The process of claim 13 , wherein said PCS has the amino acid sequence of SEQ ID NO: 3 except for

(a) an amino acid substitution at the position corresponding to position 67 of the protein of SEQ ID NO: 3, wherein the amino acid at said position is K, and an amino acid substitution at the position corresponding to position 60 of the protein of SEQ ID NO: 3;

(b) an amino acid substitution at the position corresponding to position 67 of the protein of SEQ ID NO: 3, wherein the amino acid at said position is K, and an amino acid substitution at the position corresponding to position 75 of the protein of SEQ ID NO: 3; or

(c) an amino acid substitution at the position corresponding to position 67 of the protein of SEQ ID NO: 3, wherein the amino acid at said position is K, and additional amino acid substitutions at positions corresponding to positions 60 and 75 of the protein of SEQ ID NO: 3.

19. The process of claim 13 , wherein said PCS has an amino acid sequence selected from the group consisting of SEQ ID NO: 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 and 55.

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2021

From: GÖRLICH, DIRK; FREY, STEFFEN; VERA RODRIGUEZ, ARTURO

To: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

Reel/Frame 055044/0212 →

Priority Claims (1)

EP 18177803 · Jun 14, 2018 · regional

Continuity (1)

Related Publication 20210261937A1 · Aug 26, 2021

References Cited (55)

US 7655413B2 · Butt et al. · 2010 [cited by applicant]

US 20120065107A1 · Ring et al. · 2012 [cited by applicant]

WO2019238828, Written Opinion of the Interantional Searching Authority. Dec. 19, 2019. [cited by examiner]

Witkowski et al., Biochemistry 38:11643-11650, 1999. [cited by examiner]

Tang et al., Phil Trans R Soc B 368:20120318, 1-10, 2013. [cited by examiner]

Seffernick et al., J. Bacteriol. 183(8):2405-2410, 2001. [cited by examiner]

Singh et al., Current Protein and Peptide Science 19(1):5-15, 2018. [cited by examiner]

Sadowski et al., Current Opinion in Structural Biology 19:357-362, 2009. [cited by examiner]

Lucas et al., GenBank accession No. KQK04268, Oct. 29, 2015. [cited by examiner]

UniProtKB accession No. 11HF82_BRADI published Jan. 9, 2013. [cited by examiner]

Amor-Mahjoub, M. et al., The effect of the hexahistidine-tag in the oligomerization of HSC70 constructs. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 844(2), pp. 328-334, 200… [cited by applicant]

Bachmair, a, Finley, D. & Varshavsky, a, In vivo half-life of a protein is a function of its amino-terminal residue. Science (New York, N.Y.), 234(4773), pp. 179-186, 1986. [cited by applicant]

Bohnsack, M.T., Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA, 10(2), pp. 185-191, 2004. [cited by applicant]

Butt, T.R. et al., SUMO fusion technology for difficult-to-express proteins. Protein Expression and Purification, 43(1), pp. 1-9, 2005. [cited by applicant]

Chan, P. et al., Purification of Heterotrimeric G Protein Subunits by GST-Ric-8 Association: Primary Characterization of Purified G olf. Journal of Biological Chemistry, 286(4), pp. 2625-2635, 2011. [cited by applicant]

Chant, A. et al., Attachment of a histidine tag to the minimal zinc finger protein of the Aspergillus nidulans gene regulatory protein AreA causes a conformational change at the DNA-binding site. Protein Expression and … [cited by applicant]

Chen, X., Pham, E. & Truong, K., TEV protease-facilitated stoichiometric delivery of multiple genes using a single expression vector. Protein Science, 19(12), pp. 2379-2388, 2010. [cited by applicant]

Frey, S. & Görlich, D., A new set of highly efficient, tag-cleaving proteases for purifying recombinant proteins. Journal of Chromatography A, 1337, pp. 95-105, 2014a. [cited by applicant]

Frey, S. & Görlich, D., Purification of protein complexes of defined subunit stoichiometry using a set of orthogonal, tag-cleaving proteases. Journal of Chromatography A, 1337, pp. 106-115, 2014b. [cited by applicant]

Harder, B. et al., TEV protease-mediated cleavage in [cited by applicant]

Harper, S. & Speicher, D.W., Purification of Proteins Fused to Glutathione S-Transferase. In Methods in molecular biology (Clifton, N.J.). pp. 259-280, 2011. [cited by applicant]

Hendriks, I.A. & Vertegaal, A.C.O., A comprehensive compilation of SUMO proteomics. Nature reviews. Molecular cell biology, 17(9), pp. 581-595, 2016. [cited by applicant]

Herrmann, J., Lerman, L.O. & Lerman, A., Ubiquitin and ubiquitin-like proteins in protein regulation. Circulation Research, 100(9), pp. 1276-1291, 2007. [cited by applicant]

Himeno, H., Kurita, D. & Muto, A., TmRNA-mediated trans-translation as the major ribosome rescue system in a bacterial cell. Frontiers in Genetics, 5(APR), pp. 1-13, 2014. [cited by applicant]

Katzmann, D.J., Babst, M. & Emr, S.D., Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell, 106(2), pp. 145-155, 2001. [cited by applicant]

Keiler, K.C., Biology of trans—Translation. Annual Review of Microbiology, 62(1), pp. 133-151, 2008. [cited by applicant]

Kerscher, O., Felberbaum, R. & Hochstrasser, M., Modification of proteins by ubiquitin and ubiquitin-like proteins. Annual review of cell and developmental biology, 22, pp. 159-180, 2006. [cited by applicant]

Khorasanizadeh, S., Peters, I.D. & Roder, H., Evidence for a three-state model of protein folding from kinetic analysis of ubiquitin variants with altered core residues. Nature structural biology, 3(2), pp. 193-205, 199… [cited by applicant]

Kimple, M.E., Brill, A.L. & Pasker, R.L., Overview of affinity tags for protein purification. Current Protocols in Protein Science, (SUPPL.73), pp. 608-616, 2013. [cited by applicant]

Kosobokova, E.N., Skrypnik, K.A. & Kosorukov, V.S., Overview of fusion tags for recombinant proteins. Biochemistry (Moscow), 81(3), pp. 187-200, 2016. [cited by applicant]

Kostelansky, M.S. et al., Molecular Architecture and Functional Model of the Complete Yeast ESCRT-I Heterotetramer. Cell, 129(3), pp. 485-498, 2007. [cited by applicant]

Kuwata, T. & Nakamura, T., BCL11A is a SUMOylated protein and recruits SUMO-conjugation enzymes in its nuclear body. Genes to Cells, 13(9), pp. 931-940, 2008. [cited by applicant]

Malakhov, M.P. et al., SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins. Journal of Structural and Functional Genomics, 5(1-2), pp. 75-86, 2004. [cited by applicant]

Marblestone, J.G. et al., Comparison of SUMO fusion technology with traditional gene fusion systems: enhanced expression and solubility with SUMO. Protein science: a publication of the Protein Society, 15(1), pp. 182-18… [cited by applicant]

McCoy, J. & La Ville, E., Expression and Purification of Thioredoxin Fusion Proteins. In Current Protocols in Protein Science. Hoboken, NJ, USA: John Wiley & Sons, Inc., p. 6.7.1-6.7.14, 1997. [cited by applicant]

Pattenden, L.K. & Thomas, W.G., Amylose Affinity Chromatography of Maltose-Binding Protein. In Affinity Chromatography. Totowa, NJ: Humana Press, pp. 169-190, 2008. [cited by applicant]

Rao, R.N., Allen, N.E. & Hobbs, J.N., Genetic and enzymatic basis of hygromycin B resistance in [cited by applicant]

Reverter, D. & Lima, C.D., A basis for SUMO protease specificity provided by analysis of human Senp2 and a Senp2-SUMO complex. Structure, 12(8), pp. 1519-1531 2004. [cited by applicant]

Reverter, D. & Lima, C.D., Structural basis for SENP2 protease interactions with SUMO precursors and conjugated substrates. Nature Structural & Molecular Biology, 13(12), pp. 1060-1068, 2006. [cited by applicant]

Rodriguez, Arturo Vera, “Novel export and import pathways in [cited by applicant]

Sato, M. & Toda, T., Alp7/TACC is a crucial target in Ran-GTPase-dependent spindle formation in fission yeast. Nature, 447(7142), pp. 334-337, 2007. [cited by applicant]

Shen, L. et al., SUMO protease SENP1 induces isomerization of the scissile peptide bond. Nature Structural & Molecular Biology, 13(12), pp. 1069-1077, 2006. [cited by applicant]

Suh-Lailam, B.B. & Hevel, J.M., Efficient cleavage of problematic tobacco etch virus (TEV)-protein arginine methyltransferase constructs. Analytical Biochemistry, 387(1), pp. 130-132, 2009. [cited by applicant]

Taxis, C. & Knop, M., TIPI: TEV Protease-Mediated Induction of Protein Instability. In Methods in Molecular Biology. pp. 611-626, 2012. [cited by applicant]

Vertegaal, A.C.O. et al., A proteomic study of SUMO-2 target proteins. Journal of Biological Chemistry, 279(32), pp. 33791-33798, 2004. [cited by applicant]

Wang, K.H. et al., Tuning the strength of a bacterial N-end rule degradation signal. Journal of Biological Chemistry, 283(36), pp. 24600-24607, 2008. [cited by applicant]

Woestenenk, E.A. et al., His tag effect on solubility of human proteins produced in [cited by applicant]

Xu, Z. et al., Crystal structure of the SENP1 mutant C603S-SUMO complex reveals the hydrolytic mechanism of SUMO-specific protease. The Biochemical journal, 398(3), pp. 345-352, 2006. [cited by applicant]

Yan, Y., Orcutt, S.J. & Strickler, J.E., The use of SUMO as a fusion system for protein expression and purification. Chimica oggi, 27(6), 2009. [cited by applicant]

Zuo, X., Li, S., et al., Enhanced expression and purification of membrane proteins by SUMO fusion in [cited by applicant]

Zuo, X., Mattern, M.R., et al., Expression and purification of SARS coronavirus proteins using SUMO-fusions. Protein Expression and Purification, 42(1), pp. 100-110, 2005. [cited by applicant]

International Search Report and Written Opinion for PCT/EP2019/065516, European Patent Office, Oct. 14, 2019. [cited by applicant]

“Doctoral degree regulations of the mathematics and natural sciences graduate school of the Georg-August-Universitat Gottingen,” Georg-August University School of Science (GAUSS)—RerNat-O, 2018, pp. 1-5. [cited by applicant]

Japanese Office Action for Japanese Application No. 2020-569885, dated May 30, 2023, with English translation. [cited by applicant]

Rodriguez, “Novel export and import pathways in [cited by applicant]